Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

theguardian.com

Though doctors have said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they have said it is encouraging news because it appears it will offer patients more time, even if it does not cause full remission.

Half of all people diagnosed with pancreatic cancer die within three months, and only about 3% of patients survive for five years when the disease spreads to other organs. It has the lowest survival rate of all common cancers in the UK and has a similarly poor prognosis globally.

Patients were followed for a year and a half during the trial on average and some did not see the cancer return during this period. Longer studies will be conducted to see if any of the cancers can be put into remission. During the trial, tumours stopped growing in 90% of patients, just over 60% of patients had their tumours shrink or disappear, and for about 8% of patients tumours became undetectable on CT scans.

A year after starting treatment, 76.6% of patients were alive; usually 40-45% of patients given chemotherapy alone survive a year.